CompletedNCT00026585
Tamoxifen for acute mania in bipolarity
About this title
Examination of Tamoxifen in Acute Mania in Patients With Bipolar I Disorder
Read the official source — NCT00026585Medication studyAges 18–65United States
Understand this study
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- Washington D.C.See all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateNovember 9, 2001
- Recruitment status
- Completed
- Enrollment listed in the registry
- 50
- Sponsor
- National Institute of Mental Health (NIMH)
- Sponsor type
- Government agency
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00026585
- Official title
Show the full official title
A Double-Blind Study Examining the Efficacy of the Protein Kinase C Inhibitor Tamoxifen in the Treatment of Acute Mania
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Washington D.C.
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is National Institute of Mental Health (NIMH), a government agency.
Did this study involve medication?
Yes. The study involved medication, including Tamoxifen.
Who was this study for?
Listed age limits: 18 years to 65 years.
